Medline IPO and the $35.50 Sale: Blackstone, Carlyle, H&F Sell 60M Shares, Lock-Up to Jan 2027
Some links pay us a referral fee; each one says so. Disclosure
Filing alert · free
An email when Medline files with the SEC
An email the day Medline files something new, with the link to the document on the SEC site.
Quick answer
As of November 21, 2026, the Medline Inc. (Nasdaq: MDLN, SEC CIK 2046386) document dated November 17, 2026 is not an IPO. It is a sale of 60,000,000 existing Class A shares at $35.50 by Blackstone, Carlyle, Hellman & Friedman, GIC and an Abu Dhabi Investment Authority subsidiary, for $2,103,375,000 before expenses (Form 424B4, accession 0001193125-26-468586). Medline receives nothing from it. The IPO was December 2025, at $29.00 a share. After the sale and a $200 million repurchase, the three buyout firms plus a Mills Family entity hold about 51.5% of the votes, and the lock-up on those holders runs 75 days from November 17, 2026, which is January 31, 2027 (our arithmetic). Medline pays no dividend. Debt was $12,743 million at September 26, 2026, and nine-month 2026 operating income was $1,317 million against $1,787 million a year earlier (Form 10-Q, accession 0002046386-26-000063).
Key takeaways
- The company sells nothing. All 60,000,000 shares come from selling stockholders, and the underwriters hold an option on 9,000,000 more from the same sellers. Medline is also buying back $200 million of its own Class A shares and Common Units from them at $35.05625, the price the underwriters pay: 3,788,113 shares and 1,916,994 units.
- This is the third sale by the owners since the IPO. After the December 2025 IPO at $29.00 came 75,000,000 shares at $41.00 in March 2026 and 72,554,594 shares at $37.00 in May 2026. The November price of $35.50 is the lowest of the three, and 5.8% below the $37.68 Nasdaq close on November 17, 2026 (our arithmetic).
- Blackstone and Hellman & Friedman each go from 153,327,675 shares and units to 131,885,754 after the sale, a cut of about 14% each; Carlyle goes from 187,083,713 to 176,362,328, about 6% (our arithmetic). Before the March sale the three held 215,303,036 each (our arithmetic), so Blackstone and H&F are down 39% since March and Carlyle down 18%.
- Control stays with the sellers and the Mills Family. After the sale the four holders called Designating Stockholders hold about 51.5% of the votes, with a right to name directors; the Mills Family votes are capped at 20% of all votes. Medline's Class B shares carry a vote and no dividend.
- The lock-up is 75 days, not the 180 days of the IPO. It ends January 31, 2027 (our arithmetic), earlier if Goldman Sachs or Morgan Stanley and one other representative consent. Transfers to affiliates, limited partners and for estate planning are carved out, so a fund can hand shares to its own investors inside the lock-up.
- Operating income fell while sales grew. Nine months to September 26, 2026: net sales $22,893 million (up from $20,645 million), operating income $1,317 million (down from $1,787 million), net income $696 million (down from $977 million). Interest expense dropped to $373 million from $646 million after the IPO repaid term loans. Three FDA warning letters are unresolved and a bed recall is estimated to cost $60 million to $210 million more.
- No fund we cover names Medline. BXPE's September 30, 2026 schedule and CPEP's 10-Q do not contain the word, and CAPM's March 31, 2026 annual report does not either; CAPM does list a Hellman & Friedman Capital Partners X line, the fund family that sold here.
CSV · 173 rows
Medline (MDLN): November 2026 sale, sellers' stakes, voting power, lock-up, earlier offerings, results, debt and fund holdings
173 rows from the 424B4 of November 17, 2026, the 8-K of November 18, 2026, the Q3 2026 10-Q, the 10-K for 2025, the earlier prospectuses and three evergreen private equity funds' latest reports. Form and accession number on every row.
What the document is: the fourth stock sale, and the first one with no new money for Medline
The prospectus filed November 19, 2026 is often called the Medline IPO, and it is not one. The initial public offering was priced at $29.00 in December 2025, and in it Medline Inc. sold the shares and received the proceeds. Every offering since then has been existing owners selling to the public.
| Offering | Price | Shares | Who sold | Proceeds | Source |
|---|---|---|---|---|---|
| IPO, December 2025 | $29.00 | 216,034,482 in the base deal; 248,439,654 with the option | Medline Inc. | $6,128,524,514.69 to the company on the base deal; about $7,048 million net with the option | 424B4 0001193125-25-323742; 10-K 0002046386-26-000009 |
| Secondary, March 2026 | $41.00 | 75,000,000 | Selling stockholders | $3,038,100,000 before expenses | 424B4 0001193125-26-096456 |
| Secondary, May 2026 | $37.00 | 72,554,594 | Selling stockholders | $2,650,963,478 before expenses | 424B4 0001193125-26-239247 |
| Secondary, November 2026 | $35.50 | 60,000,000 (option: 9,000,000 more) | Selling stockholders | $2,103,375,000 before expenses; $200 million more by private repurchase | 424B4 0001193125-26-468586; 8-K 0001193125-26-467193 |
The IPO proceeds went mostly to debt: the 10-K says $731 million repaid all euro term loans and $3,292 million repaid part of the dollar term loans, and some of the money bought equity from earlier owners. In November the cover page says: “We will not receive any proceeds from the sale of shares of our Class A common stock by the selling stockholders.” The underwriters are paid $0.44375 a share, $26,625,000 in total, by the sellers. The expected delivery date is November 23, 2026.
The price path is a fact of the three prospectuses, not a forecast: $41.00, then $37.00, then $35.50. Each sale was priced at a discount to the previous close; the November price is 5.8% below the $37.68 close of November 17, 2026 (our arithmetic). This page does not say where the shares will trade.
Who sells, and what each keeps
Five holders sell. The table uses the prospectus's base numbers and its price of $35.05625 a share after the discount; gross amounts are our arithmetic.
| Seller | Shares sold (base) | Shares sold (with option) | Gross at $35.05625 (our arithmetic) | Class A plus Class B before (our arithmetic) | After sale and repurchase (our arithmetic) |
|---|---|---|---|---|---|
| Blackstone funds | 19,325,955 | 22,224,848 | $677.5 million | 153,327,675 | 131,885,754 (10.07% of 1,309,616,327) |
| Carlyle funds | 9,057,205 | 10,415,787 | $317.5 million | 187,083,713 | 176,362,328 (13.47%) |
| Hellman & Friedman funds | 18,878,907 | 21,710,743 | $661.8 million | 153,327,675 | 131,885,754 (10.07%) |
| GIC and its affiliate | 9,530,870 | 10,960,500 | $334.1 million | 74,634,102 Class A | 64,196,988 Class A |
| Abu Dhabi Investment Authority subsidiary | 3,207,063 | 3,688,122 | $112.4 million | 25,941,265 Class A | 22,429,258 Class A |
| Mozart HoldCo (Mills Family entity) | none | none | none | 234,308,304 | 234,308,304 (17.89%) |
Class A plus Class B is the economic stake: each Class B share matches one Common Unit of Medline Holdings, exchangeable one for one into Class A. The denominator is 1,309,616,327 shares assuming every unit is exchanged, which the prospectus gives. The change for Blackstone adds up exactly: 19,325,955 sold, repurchases of 1,211,686 Class A shares and 625,926 Common Units, and an in-kind distribution of 278,354 shares to its own affiliates and limited partners (our arithmetic from the footnotes). Carlyle and H&F have similar in-kind distributions of 802,977 and 767,910 shares after the closing, and the prospectus says recipients would be subject to the lock-up.
At the $35.50 offering price, the 1,309,616,327 shares and units are $46.5 billion (our arithmetic), on top of the debt below. That is a statement about the offer price, not a view of value.
Three sales, one pattern: the sponsors have been selling down evenly, and Carlyle less
The three prospectuses show each sponsor's holdings before and after (no option). Class A plus Class B are summed by us.
| Holder (Class A plus Class B, our arithmetic) | Before March 2026 sale | After March sale | After May sale | After November sale and repurchase | Change since March |
|---|---|---|---|---|---|
| Blackstone funds | 215,303,036 | 190,764,494 | 153,327,675 | 131,885,754 | down 83.4 million (38.7%) |
| Carlyle funds | 215,303,036 | 190,764,494 | 187,083,713 | 176,362,328 | down 38.9 million (18.1%) |
| Hellman & Friedman funds | 215,303,036 | 190,764,494 | 153,327,675 | 131,885,754 | down 83.4 million (38.7%) |
Each prospectus gives its own before and after figures, and the "after" of one differs slightly from the "before" of the next (for example Blackstone's March "after" and May "before" differ by about 3.7 million shares and units), because repurchases and in-kind distributions are counted in the footnotes. The three holders started equal at 215,303,036 each before March. Carlyle did not sell in May, which is why it now holds 44.5 million more shares and units than Blackstone or H&F (our arithmetic).
Besides the four, the table shows GIC (74,634,102 Class A, 8.5% before the sale), Capital Research Global Investors (47,768,233 Class A, 5.4%) and FMR LLC (46,929,204 Class A, 5.3%) above 5% of Class A.
Control: 51.5% of the votes, a family cap and directors named by the holders
Medline has two classes of stock that vote together, one vote each. Class A is the traded stock. Class B has no economic rights, and every share is matched to a Common Unit held by a pre-IPO owner, so it is a voting right attached to the units.
| Holder | Voting power before the sale | After the sale and repurchase (no option) | Source |
|---|---|---|---|
| Blackstone | 11.7% | 10.1% | 424B4 principal and selling stockholders table |
| Carlyle | 14.2% | 13.5% | 424B4 |
| Hellman & Friedman | 11.7% | 10.1% | 424B4 |
| Mozart HoldCo (Mills Family) | 17.8% | 17.8% | 424B4 |
| The four together (Designating Stockholders) | 55.4% (our arithmetic) | 51.5% (50.9% with the full option) | 424B4 risk factors |
| GIC | 5.7% | 4.9% | 424B4 |
| Abu Dhabi Investment Authority | 2.0% | 1.7% | 424B4 |
| Directors and executive officers as a group (18 persons) | 1.2% | 1.2% | 424B4 |
Three terms matter beyond the percentages. First, the prospectus says the company agreed to nominate directors chosen by the Designating Stockholders, subject to ownership thresholds. Second, the Mills Family cap: they “are not entitled to cast votes, or provide consent, with respect to any shares of capital stock of Medline Inc. owned by them representing, in the aggregate, more than 20% of the total number of votes” — so the family's 17.8% sits under its cap. Third, the Mozart HoldCo entity is owned by members of the Mills Family and trusts for their benefit, with no person or group holding more than 50% of its voting power. The prospectus does not use the term “controlled company”; it describes the 51.5% as significant influence.
The risk factor on conflicts also states that 31.6% of the Common Units will be held by Continuing Common Unitholders, which includes some sponsor interests, and that these holders can have interests that differ from Class A holders, for example on distributions and a tax receivable agreement under which Medline pays pre-IPO owners 90% of certain tax benefits.
Two further facts from the prospectus are not usually on a quote screen. Certain Blackstone and Carlyle funds have pledged substantially all of their Class A and Class B shares under margin loan agreements, with foreclosure rights if the loans default. And because affiliates of Blackstone and Carlyle own more than 10% of Medline and will receive more than 5% of net proceeds, Blackstone Securities Partners and TCG Capital Markets, as underwriters, are deemed to have a conflict of interest under FINRA Rule 5121; the prospectus says no qualified independent underwriter is required because a bona fide public market exists.
Lock-up: 75 days to January 31, 2027, with a long list of exceptions
The company, its officers and directors, the Principal Stockholders and the Other Pre-IPO Investors agreed not to sell or hedge shares until “75 days after the date of this prospectus”, which is January 31, 2027 (our arithmetic from November 17, 2026; a Sunday). Goldman Sachs or Morgan Stanley plus one more representative can release it. The IPO lock-up was 180 days from December 16, 2025, which was June 14, 2026 (our arithmetic); the March 2026 prospectus says the banks agreed to release the lock-up for the shares sold in that offering.
| Lock-up item | What the prospectus says |
|---|---|
| Length | 75 days from November 17, 2026; ends January 31, 2027 (our arithmetic) |
| Who is bound | Medline, its officers and directors, Principal Stockholders and Other Pre-IPO Investors |
| Who can release | Goldman Sachs & Co. LLC or Morgan Stanley & Co. LLC, plus one additional representative, with notice to the others |
| Allowed without consent | gifts and estate planning, transfers to affiliates and funds under common management, distributions to limited partners and members, court orders, third-party tender offers approved by the board, and open-market purchases made after the offering |
| Trading plans | a Rule 10b5-1 plan may be set up if no transfers occur under it during the lock-up |
| Sellers' in-kind distributions | 278,354 shares (Blackstone), 802,977 (Carlyle) and 767,910 (H&F) may be handed to affiliates and limited partners after closing, who must sign a lock-up |
The exceptions mean that the lock-up is not the date when sponsor-linked shares can first reach other hands: distributions to limited partners are allowed inside it. The date after which sales on the open market by the holders themselves are open is January 31, 2027, unless the banks release it.
Medline's results and debt
Medline reported nine-month 2026 net sales of $22,893 million, 10.9% higher than the $20,645 million a year earlier (our arithmetic), but operating income of $1,317 million against $1,787 million.
| USD million | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 | FY2025 | FY2024 |
|---|---|---|---|---|---|---|
| Net sales | 7,856 | 7,115 | 22,893 | 20,645 | 28,432 | 25,507 |
| Operating income | 500 | 574 | 1,317 | 1,787 | 2,212 | 2,146 |
| Interest expense, net | 118 | 213 | 373 | 646 | 812 | 864 |
| Net income | 318 | 322 | 696 | 977 | 1,157 | 1,200 |
| Provision for income taxes | 68 | 23 | 216 | 65 | 91 | 46 |
Of the nine-month net income, $384 million belongs to Medline Inc. and $312 million to noncontrolling interests, the owners of Common Units. The nine-month figure for other operating expense is $353 million against $30 million. The 10-Q's reconciliation says a fire at the Tracy distribution center, remediation after FDA observations and warning letters, and bed recall costs are included in the 2026 periods. Interest expense fell by $273 million in nine months, after IPO money repaid term loans, while the tax provision rose to $216 million from $65 million.
| Debt (USD million) | September 26, 2026 | December 31, 2025 |
|---|---|---|
| Unsecured fixed rate, due 2029 (5.61% average) | 2,500 | 2,500 |
| Secured fixed rate, 2029 to 2033 (4.81% average at September 26, 2026) | 7,500 | 6,000 |
| Secured variable rate (6.07% average at September 26, 2026; 7.10% at December 31, 2025) | 2,743 | 4,255 |
| Total debt | 12,743 | 12,755 |
| Cash and cash equivalents | 2,321 | 1,939 |
| Short-term investments | 1,287 | none |
In May 2026 Medline issued $1,250 million of 5.000% senior secured notes due June 15, 2031 and $750 million of 5.250% notes due June 15, 2033, refinanced term loans and redeemed $500 million of 6.250% notes due 2029. Total debt is almost unchanged at $12.7 billion, but more of it is fixed. The company does not receive money from the November sale, so its debt does not change because of it. Instead the company spends cash: the $200 million repurchase counts against a $1 billion share repurchase program its board authorized in October 2026.
Dividend. “We have no current plans to pay dividends on our Class A common stock following this offering.” Class B holders get no dividends. Medline Holdings makes tax distributions to unit holders, which are not dividends to Class A holders.
FDA and the bed recall. The 10-Q reports three unresolved FDA warning letters, on the Northfield, Glens Falls and Waukegan facilities. On September 16, 2026 Medline began a market exit for its Medline Brand beds. The affected products had about $50 million of net sales in the 12 months to September 26, 2026, and the company estimates incremental costs of $60 million to $210 million, mostly in the fourth quarter of 2026 and 2027. The November prospectus adds that a November 13, 2026 press release gave information on reports of deaths and serious injuries tied to the beds as of November 8, 2026. These are the facts in the filings; whether they matter to the share price is not something these documents answer.
Which funds that individuals hold own Medline through these sponsors
Blackstone, Carlyle and Hellman & Friedman each sell through their buyout funds, and individuals reach those funds through evergreen private equity vehicles. We checked the latest filed schedules of the ones we cover for the name Medline.
| Fund and document | Result for Medline | What the schedule does show |
|---|---|---|
| Blackstone Private Equity Strategies Fund (BXPE), Form 10-Q for September 30, 2026, accession 0001930054-26-000038 | not named | Healthcare equity investments of $1,572,998 thousand, 8.0% of net assets, shown only as “Other Investment(s) in Equity” by region, with no company names |
| Carlyle Private Equity Partners Fund (CPEP), Form 10-Q for September 30, 2026, accession 0002065337-26-000055 | not named | the filing text has no match for Medline, Mozart or MDLN |
| Carlyle AlpInvest Private Markets Fund (CAPM), annual report for March 31, 2026, accession 0001899610-26-000006 | not named | lists funds and holding vehicles, not companies by name; includes Hellman & Friedman Capital Partners X at fair value $612,448 and Hellman & Friedman Capital Partners IX (Parallel) at $8,801,011, out of net assets of $4,393,988,465 |
So the honest answer is that no evergreen fund we cover shows a Medline line by name. That does not mean none holds it. BXPE's schedule groups holdings without names, and co-investment vehicles are often not named. CAPM's Hellman & Friedman Capital Partners X line is the fund that the prospectus names as the H&F seller entities (Hellman & Friedman Capital Partners X (Parallel), L.P. and related entities); the CAPM line is 0.014% of net assets (our arithmetic: $612,448 divided by $4,393,988,465), and the schedule does not say what that fund owns. CAPM's half-year report for September 30, 2026 is due around December 2026 and is the next place to look. Our pages on these funds: BXPE redemptions, CAPM tender offers, CPEP and the ten evergreen funds' Q3 10-Qs.
The two sponsors that are public companies have their own pages: Blackstone (BX) and Carlyle (CG). Neither page mentions Medline.
For another recent case of owners selling through the public market, see Janus Living (JAN), where the company itself sold the shares, and for an IPO priced the same week, Anthropic's 424B4.
What a holder can do
- Separate the three events. A December 2025 IPO that raised money for Medline, two sales and a third in November that raised money for the sellers. The November sale does not change the company's debt or cash.
- Put January 31, 2027 on the calendar, with its exceptions. That is the lock-up end (our arithmetic). It does not stop distributions to limited partners before then.
- Look at who votes. Four holders and a 20% family cap decide most outcomes. A Class A share carries one vote, in the same class as the holders above.
- Watch the next two documents. The 8-K or Form 4 filings after the November 23, 2026 closing will show whether the underwriters used the 9,000,000-share option, and the CAPM half-year report will show whether a Hellman & Friedman line changed.
- Size the position. If Medline, a private equity fund and a healthcare fund together make up a large part of a portfolio, one conversation with a qualified adviser about how they overlap may be worth having.
This is analysis of public documents, not investment, legal or tax advice.
FAQ
Figures are from Medline Inc. (SEC CIK 2046386) filings read on EDGAR on November 21, 2026: Form 424B4 dated November 17, 2026 and filed November 19, 2026 (accession 0001193125-26-468586); Form 8-K of November 18, 2026 (0001193125-26-467193); Form 10-Q for the quarter ended September 26, 2026 (0002046386-26-000063); Form 10-K for 2025 (0002046386-26-000009); Forms 424B4 of December 18, 2025, March 6, 2026 and May 26, 2026 (0001193125-25-323742, 0001193125-26-096456, 0001193125-26-239247); Blackstone Private Equity Strategies Fund Form 10-Q for September 30, 2026 (0001930054-26-000038); Carlyle Private Equity Partners Fund Form 10-Q for September 30, 2026 (0002065337-26-000055); and Carlyle AlpInvest Private Markets Fund Form N-CSR for March 31, 2026 (0001899610-26-000006). Sums of Class A and Class B, percentages of the fully exchanged share count, gross amounts at the underwriters' price and dates computed from day counts are our arithmetic.